Iovance Biotherapeutics

6 followers


Iovance Biotherapeutics (NASDAQ: IOVA) aims to improve patient care for people living with cancer. Iovance is investigating T cell-based therapies, known as tumor infiltrating lymphocytes (TIL), which use a patient’s own immune cells to attack cancer.

Industries

Employees

201-500

Links


Org chart

Frederick G. Vogt
Interim CEO, President & General Counsel
Collapse
Friedrich Graf Finckenstein
Chief Medical Officer
Howard B. Johnson
Chief Business Officer
Brian Shew
SVP, Head of Digital & Information Technology
Tracy Winton
EVP, Human Resources
Kevin Smyth
EVP, Quality
Hequn Yin
SVP, Research
Ahmed Tawashi
Vice President, Research Alliances
Jessica Reckner
Senior Director Of Marketing
Mariam Mirgoli
Senior Vice President, Data Management And Solutions
Renee Doggett
Director, Quality Control Compliance
Stefanie Bulilan
Sr. Director Quality Systems And Compliance
Sean Rocca
Executive Counsel
Dan Kirby
Chief Commercial Officer (cco)
Sara Pellegrino
Svp, Investor Relations & Corporate Communications
Marcela Batista-Mujica
Executive Assistant To President & CEO
Kun Wang
Senior Patent Counsel
Jonathan W.
Associate General Counsel
Matthew Rosinack
Senior Vice President Finance
Michele Fernandes
SVP Portfolio Management
Jackie Holcomb (Suzuki)
VP Of Finance, Corporate Controller
Shanna Wu
Sr. Manager, Global Consolidation

Board & advisors